Cargando…

AB004. Peyronie’s disease: 2017 update

Peyronie’s disease (PD) is characterized by a symptom complex of penile plaque (fibrotic nodule), deformity (bending, indentation or shortening), painful erection and erectile dysfunction. The prevalence in China is unknown. The natural history of the disease is reported to be progressive as 45% of...

Descripción completa

Detalles Bibliográficos
Autor principal: Lue, Tom F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565592/
http://dx.doi.org/10.21037/tau.2017.s004
_version_ 1783258409631481856
author Lue, Tom F.
author_facet Lue, Tom F.
author_sort Lue, Tom F.
collection PubMed
description Peyronie’s disease (PD) is characterized by a symptom complex of penile plaque (fibrotic nodule), deformity (bending, indentation or shortening), painful erection and erectile dysfunction. The prevalence in China is unknown. The natural history of the disease is reported to be progressive as 45% of the patient experience worsening of the symptoms 1 year after diagnosis. However, the prevalence and disease characteristics in Chinese are unknown. Many treatment options have been used for PD with varying degrees of success. In this article, we review and summarize the current literature pertaining to all pharmacotherapies (oral, intralesional, iontophoresis, and topical) and minimally invasive treatments available for PD (vacuum, traction device, shock wave therapy, and radiation treatment). Additionally, we discuss emerging therapies for PD that are still in pre-clinical development, including stem cell therapy.
format Online
Article
Text
id pubmed-5565592
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-55655922017-09-01 AB004. Peyronie’s disease: 2017 update Lue, Tom F. Transl Androl Urol Plenary Session Peyronie’s disease (PD) is characterized by a symptom complex of penile plaque (fibrotic nodule), deformity (bending, indentation or shortening), painful erection and erectile dysfunction. The prevalence in China is unknown. The natural history of the disease is reported to be progressive as 45% of the patient experience worsening of the symptoms 1 year after diagnosis. However, the prevalence and disease characteristics in Chinese are unknown. Many treatment options have been used for PD with varying degrees of success. In this article, we review and summarize the current literature pertaining to all pharmacotherapies (oral, intralesional, iontophoresis, and topical) and minimally invasive treatments available for PD (vacuum, traction device, shock wave therapy, and radiation treatment). Additionally, we discuss emerging therapies for PD that are still in pre-clinical development, including stem cell therapy. AME Publishing Company 2017-08 /pmc/articles/PMC5565592/ http://dx.doi.org/10.21037/tau.2017.s004 Text en 2017 Translational Andrology and Urology. All rights reserved.
spellingShingle Plenary Session
Lue, Tom F.
AB004. Peyronie’s disease: 2017 update
title AB004. Peyronie’s disease: 2017 update
title_full AB004. Peyronie’s disease: 2017 update
title_fullStr AB004. Peyronie’s disease: 2017 update
title_full_unstemmed AB004. Peyronie’s disease: 2017 update
title_short AB004. Peyronie’s disease: 2017 update
title_sort ab004. peyronie’s disease: 2017 update
topic Plenary Session
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565592/
http://dx.doi.org/10.21037/tau.2017.s004
work_keys_str_mv AT luetomf ab004peyroniesdisease2017update